 |
Advertisement:
Pharmaceutical Technology Solid Dosage Combo
Increase your knowledge of solid dosage technology and solid dose tablet manufacturing processes. These comprehensive pharmacology reference guides cover a variety of solid dosage form principles such as solid oral dosage forms, powders, mixing and blending, excipients, tableting, and coating. Stay current with compressed tablet manufacturing processes, solid dosage processing equipment, tablet-pressing processes, and pharmaceutical industry trends in oral solid dosage manufacturing and solid dosage form development.
Click here |
|
|
 |
 
Advertisement:
FREE WHITEPAPER: The Key to Tableting Success
Learn about common pitfalls, critical questions to ask your tooling provider, and the basics of tool steel selection.  Learn More! |
 |
USP Launches Initiative to Fight Counterfeit Drugs in Sub-Saharan Africa
New Center for Pharmaceutical Advancement and Training increases number of experts and available tools in Sub-Saharan countries.
Lilly’s Enzastaurin Disappoints in Phase III Trial
Eli Lilly reported that enzastaurin did not meet the primary endpoint in a Phase III study, which evaluated the agent as a monotherapy for the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL).
Advertisement:
Minimizing Out-of-Specification (OOS) Errors Using a Risk-based Gravimetric Approach
Live Webcast: Wednesday, May 22, 2013 at 11:00 EST, 15:00 UTC (GMT), 16:00 BST
Register Free at  www.pharmtech.com/minimizingOOS |
GSK Announces Plans to Share Clinical Trial Data
In its commitment to transparency, GlaxoSmithKline (GSK) has outlined plans to share detailed data from its clinical trials. GSK is to establish a new online system that will enable researchers to request access to anonymised patient level data.
Advertisement:
Cleaning Validation: Science, Risk, and Novel Approaches to Testing
Live Webcast: Tuesday, June 4, 2013 at 11:00 am EDT
Register Free at  www.pharmtech.com/testing |
European Medicines Agency Changes Procedures for Orphan Drug Fees
EMA streamlines orphan drug application procedure.
Advertisement:
Avoid the 483–Unconventional Approaches to Elevate Your Quality Program
Live Webcast: Thursday, May 23, 2013 at 8:00am PDT/ 11:00am EDT
Register Free at  www.spectroscopyonline.com/ramananalysis
|
USP Workshop Addresses Moisture Permeation into Packages
The workshop will cover a proposed new method for measuring moisture vapor transmission rate.
Advertisement:
Risk Mitigation for Alcohol-Dose Dumping in Controlled Release Forms
Live Webcast: Thursday, May 23, 2013 at 10:00 am EST
Register Free at  www.pharmtech.com/alcohol
|
Amgen Forms New Joint Venture to Commercialize Vectibix in China
Amgen and Zhejiang Beta Pharma have signed an agreement to form a joint venture to commercialize Amgen's Vectibix (panitumumab) in the Chinese market. The aim is to quickly and efficiently deliver Vectibix to patients in China. Vectibix is a fully human anti-epidermal growth factor receptor antibody approved by FDA for the treatment of metastatic colorectal cancer.
Takeda to Acquire Inviragen for up to $250 Million
Takeda and US vaccines maker Inviragen jointly announced that they have entered into a definitive agreement for Takeda to acquire Inviragen for an upfront payment of $35 million and future payments of up to $215 million upon achievement of key commercial milestones, linked to the progress of clinical development.
|
|
 |
|
|
|
|
|
|
|
| What has been the most significant benefit of applying quality-by-design (QbD) principles? |
|
Better process understanding: |
67% |
| |
|
Increased efficiency or reduced waste |
9% |
| |
|
|
|
Shorter process times |
5% |
| |
|
|
|
Reduced expenses |
4% |
| |
|
|
|
Improved ease of making changes |
15% |
| |
|
|
This week we would like to know...
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
|
|
|
|
Contact Us
Click here to contact editorial.
Click here to contact sales. |
|
|
